

- **Name:** Hyehyun Jeong
  - **Current Position & Affiliation:** Assistant Professor / Asan Medical Center,  
University of Ulsan College of Medicine
  - **Country:** Korea
- 

- **Educational Background:**

B.S. Catholic University of Daegu, Daegu, Korea, 2009-2015

M.S. University of Ulsan College of Medicine, Seoul, Korea, 2018-2020

Ph.D. University of Ulsan College of Medicine, Seoul, Korea, 2020-2022

- **Professional Experience:**

Residency, Department of Internal Medicine, Asan Medical Center, Seoul, Korea, 2016-2020

Clinical fellowship, Department of Oncology, Asan Medical Center, Seoul, Korea, 2020-2022

Assistant professor, Department of Oncology, Asan Medical Center, Seoul, Korea, 2025-

- **Professional Organizations:**

The Korean Association of Internal Medicine

Korean Society of Medical Oncology

Korean Cancer Study Group

- **Main Scientific Publications:**

Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. *Hepatology*. 2023 May 1;77(5):1540-1549.

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study. *Eur J Cancer*

. 2024 Sep;208:114194.

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. *Int J Cancer*

. 2021 Apr 27. doi: 10.1002/ijc.33613.

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. *Eur J Nucl Med Mol Imaging*. 2025 May;52(6):2096-2106.